Trenchant Biosystems released internal and external validation data for its AutoCell automated cell‑and‑gene‑therapy (CGT) manufacturing prototype, reporting a reduction of vein‑to‑vein timelines from industry standard six weeks to 2.5 days and a seven‑fold increase in gene‑modified cell yield. The company said the platform could cut costs by up to 80% and produce clinical doses using only 25% of a fresh apheresis. External partner Invetech validated washing, selection, and activation unit operations, lending third‑party credibility to process control claims. Trenchant CEO Jon Ellis framed the platform as a route to make CGTs scalable and affordable enough to become first‑line therapies if performance holds up in further validations and regulatory pathways. Who’s involved: Trenchant Biosystems, Invetech; company press releases and validation data. The claims are pre‑commercial and require regulatory, reproducibility, and scale demonstration before clinical manufacturing adoption.